Compare TOUR & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOUR | PYXS |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.0M | 71.6M |
| IPO Year | N/A | N/A |
| Metric | TOUR | PYXS |
|---|---|---|
| Price | $0.58 | $1.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 91.1K | ★ 548.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.27 | N/A |
| Revenue Next Year | $10.18 | N/A |
| P/E Ratio | $90.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.58 | $0.83 |
| 52 Week High | $1.17 | $5.55 |
| Indicator | TOUR | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 33.79 | 35.20 |
| Support Level | $0.62 | $1.28 |
| Resistance Level | $0.65 | $1.39 |
| Average True Range (ATR) | 0.02 | 0.12 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 29.79 | 11.91 |
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.